세계의 POC(Point-of-Care) 진단 시장 : 플랫폼, 용도, 샘플 유형, 최종사용자별 - 예측(-2030년)

The global point-of-care diagnostics market is projected to reach $43.1 billion by 2030, at a CAGR of 5.1% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth in the point-of-care diagnostics market is mainly attributed to the rapidly growing demand for cost-efficient PoC tests, the outbreak of COVID-19, and growing funding for PoC diagnostics tests. However, pricing pressure due to fluctuations in reimbursements restrains the growth of this market. Increasing demand for PoC diagnostics in emerging economies is expected to create opportunities in the market.

Based on offering, in 2023, the consumables segment is expected to account for the largest share of the market. Diagnostic kits are designed to provide highly accurate results with minimal risk of user error. They are pre-packaged with all the necessary materials and reagents, ensuring that the correct amounts are used, thus reducing the risk of contamination, contributing to the segment's largest share.

Based on platform, the molecular diagnostics segment is projected to register the highest CAGR during the forecast period. The tests are commonly used for the detection of viruses such as COVID-19 and flu, while LAMP tests are used for the detection of bacteria and viruses, such as tuberculosis and human papillomavirus (HPV). These tests can provide results within 30 minutes to an hour, depending on the complexity of the test and the type of instrument used. The shorter turnaround time of test results drives the market for molecular diagnostics.

Based on application, in 2023, the blood glucose monitoring segment is expected to account for the largest share of the global point-of-care diagnostics market. PoC devices are widely used for monitoring blood glucose levels. These devices offer reliable quantitative results and are portable, inexpensive, and easy to use, driving the segment growth. Additionally, they enable healthcare professionals to make immediate treatment decisions in response to glycemic fluctuations in hospitalized patients and can also be used by diabetic patients at home to monitor their glucose levels frequently.

Based on sample type, in 2023, the blood sample type segment is expected to account for the largest share of the global point-of-care diagnostics market. Blood sample testing has many benefits, such as determining infections and risks for various health conditions, monitoring the status and progression of chronic diseases, checking treatment success, and in some cases, early disease diagnosis, contributing to the largest share of the segment.

Based on end-user, in 2023, the hospital segment is expected to account for the largest share of the global point-of-care diagnostics market. Hospitals perform various tests to diagnose medical conditions and ensure proper clinical treatment and prevention planning. Factors such as the urgency in medical decision-making, increasing healthcare expenditure, rising prevalence of healthcare-associated infections (HAIs), and the rising number of hospitals and clinics across emerging markets are driving the demand for point-of-care diagnostic kits for use in hospitals & clinics.

An in-depth analysis of the geographical scenario of the global point-of-care diagnostics market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the point-of-care diagnostics market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's large share is attributed to the region's highly developed diagnostics infrastructure, the trend of PoC testing, the high prevalence of chronic diseases coupled with growth in the aging population, the rising number of inpatient admissions, and the high adoption of self-testing kits among the general population.

The key players operating in the global point-of-care diagnostics market are Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Chembio Diagnostics, Inc. (U.S.), EKF Diagnostics Holdings plc (U.K.), Trinity Biotech plc (Ireland), Werfen (Spain), Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.), and bioMerieux S.A. (France).

Scope of the Report:

Point-of-Care Diagnostics Market Assessment-by Offering

• Consumables
• Instruments
• Software and Services

Point-of-Care Diagnostics Market Assessment-by Platform

• Lateral Flow Assays
• Molecular Diagnostics
• Other Platforms

(Other platforms include coagulation tests, dipsticks, cholesterol and glucose monitoring systems, and other point-of-care diagnostic platforms)

Point-of-Care Diagnostics Market Assessment-by Application

• Blood Glucose Monitoring
• Infectious Disease Testing
  • Parasitic Infection Testing
  • Blood-borne Infection Testing
• Hepatitis
• HIV
• Other Blood-borne Infections
  • Respiratory Infection Testing
• Influenza
• Pneumonia
• Other Respiratory Infection Testing
  • Healthcare-associated Infection (HAI) Testing
  • Gastrointestinal (GI) Infection Testing
• Salmonellosis
• E. Coli Infections
• Other GI Infections
  • Other Infectious Disease Testing
• COVID-19 Testing
• Tumor/Cancer Markers Testing
• Pregnancy And Fertility Testing
  • Pregnancy Testing
  • Fertility Testing
• Cardiac Marker/Cardiac Metabolism Testing
• Cholesterol/Lipid Profile Testing
• Coagulation Testing
  • Prothrombin Time (PT/INR) Testing
  • Activated Clotting Time (ACT/APTT) Testing
  • Other Coagulation Testing
• Hematology
• Drugs Of Abuse Testing
• Urinalysis
• Other PoC Testing

(Other respiratory infections testing include strep infections and respiratory syncytial virus (RSV). Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis. Other blood-borne diseases include syphilis and brucellosis. Other infectious disease testing includes meningitis, hand, foot, and mouth disease (HFMD), and mononucleosis. Other coagulation testing includes fibrinogen level and platelet count. Other PoC testing includes tropical diseases and sexually transmitted diseases)

Point-of-Care Diagnostics Market Assessment-by Sample Type

• Blood Sample
• Nasopharyngeal swab
• Urine Sample
• Saliva Sample
• Other Sample Types

(Other sample types include stool, cervical swab, buccal swab, hair, vaginal swab, and semen)

Point-of-Care Diagnostics Market Assessment-by End User

• Hospitals
• Home care/self-testing
• Physician Offices & Ambulatory Care Settings
• Diagnostics Laboratories
• Other End User

(Other end users include nursing homes, long-term care centers, pharmacies, urgent care facilities, schools, airports, hotels, and workplaces)

Point-of-Care Diagnostics Market Assessment-by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Market Definition & Scope

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency & Limitation
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Process
• 2.2. Process of Data Collection & Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
    • 2.3.1.1. Bottom-up Approach
    • 2.3.1.2. Top-down Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Increasing Prevalence of Chronic Diseases
  • 4.2.2. Innovations in PoC Tests
  • 4.2.3. Development of CLIA-waived PoC Tests
  • 4.2.4. Lack of Skilled Technicians for Performing Lab Tests
• 4.3. Restraints
  • 4.3.1. Pricing Pressure Due to Fluctuations in Reimbursements
• 4.4. Opportunities
  • 4.4.1. Emerging Markets
  • 4.4.2. Healthcare Professionals' Increasing Preference for PoC Tests Over Other Lab Tests
• 4.5. Challenges
  • 4.5.1. Lack of Awareness Regarding the Use of PoC Devices
• 4.6. Technology Trends
  • 4.6.1. Lateral Flow Assays Containing DNA Nanostructures
  • 4.6.2. Rapid Real-time Polymerization Chain Reaction (PCR) Tests
  • 4.6.3. Smartphone-based Detection Platforms
  • 4.6.4. Nanoelectronic Biosensors in Point-of-Care Diagnostics
• 4.7. Regulatory Analysis
  • 4.7.1. U.S.
  • 4.7.2. Canada
  • 4.7.3. Europe
  • 4.7.4. China
  • 4.7.5. Japan
  • 4.7.6. Latin America
  • 4.7.7. Saudi Arabia
• 4.8. Pricing Analysis

5. Point-of-Care Diagnostics Market Assessment-by Offering

• 5.1. Overview
• 5.2. Consumables
• 5.3. Instruments
• 5.4. Software And Services

6. Point-of-Care Diagnostics Market Assessment-by Platform

• 6.1. Overview
• 6.2. Lateral Flow Assays
• 6.3. Molecular Diagnostics
• 6.4. Other Platforms

7. Point-of-Care Diagnostics Market Assessment-by Application

• 7.1. Overview
• 7.2. Blood Glucose Monitoring
• 7.3. Infectious Disease Testing
  • 7.3.1. Parasitic Infections Testing
  • 7.3.2. Blood-borne Infections Testing
    • 7.3.2.1. Hepatitis
    • 7.3.2.2. HIV
    • 7.3.2.3. Other Blood-borne Infections
  • 7.3.3. Respiratory Infections Testing
    • 7.3.3.1. Influenza
    • 7.3.3.2. Pneumonia
    • 7.3.3.3. Tuberculosis (TB)
    • 7.3.3.4. Other Respiratory Infections Testing
  • 7.3.4. Healthcare-associated Infections (HAI) Testing
  • 7.3.5. Gastrointestinal Infections Testing
    • 7.3.5.1. Salmonellosis
    • 7.3.5.2. E. Coli Infections
    • 7.3.5.3. Other GI Infections
  • 7.3.6. Other Infectious Diseases Testing
• 7.4. COVID-19 Testing
• 7.5. Tumor/Cancer Markers Testing
• 7.6. Pregnancy And Fertility Testing
  • 7.6.1. Pregnancy Testing
  • 7.6.2. Fertility Testing
• 7.7. Cardiac Marker/Cardiac Metabolism Testing
• 7.8. Cholesterol/Lipid Profile Testing
• 7.9. Coagulation Testing
  • 7.9.1. Prothrombin Time (PT/INR) Testing
  • 7.9.2. Activated Clotting Time (ACT/APTT) Testing
  • 7.9.3. Other Coagulation Testing
• 7.10. Hematology
• 7.11. Drugs of Abuse Testing
• 7.12. Urinalysis
• 7.13. Other PoC Testing

8. Point-of-Care Diagnostics Market Assessment-by Sample Type

• 8.1. Overview
• 8.2. Blood Sample
• 8.3. Nasopharyngeal Swab
• 8.4. Urine Sample
• 8.5. Saliva Sample
• 8.6. Other Sample Types

9. Point-of-Care Diagnostics Market Assessment-by End User

• 9.1. Overview
• 9.2. Hospitals
• 9.3. Home Care/Self-testing
• 9.4. Physician Offices & Ambulatory Care Settings
• 9.5. Diagnostics Laboratories
• 9.6. Other End Users

10. Point-of-Care Diagnostics Market Assessment-by Geography

• 10.1. Overview
• 10.2. North America
  • 10.2.1. U.S.
  • 10.2.2. Canada
• 10.3. Europe
  • 10.3.1. Germany
  • 10.3.2. France
  • 10.3.3. U.K.
  • 10.3.4. Italy
  • 10.3.5. Spain
  • 10.3.6. Rest of Europe
• 10.4. Asia-Pacific
  • 10.4.1. China
  • 10.4.2. Japan
  • 10.4.3. India
  • 10.4.4. Rest of Asia-Pacific
• 10.5. Latin America
  • 10.5.1. Brazil
  • 10.5.2. Mexico
  • 10.5.3. Rest of Latin America
• 10.6. Middle East & Africa

11. Competitive Landscape

• 11.1. Introduction
• 11.2. Key Growth Strategies
• 11.3. Competitive Dashboard
  • 11.3.1. Industry Leaders
  • 11.3.2. Market Differentiators
  • 11.3.3. Vanguards
  • 11.3.4. Emerging Companies
• 11.4. Market Share Analysis (2022)
  • 11.4.1. Abbott Laboratories
  • 11.4.2. F. Hoffmann-La Roche Ltd
  • 11.4.3. Siemens Healthineers AG
  • 11.4.4. Danaher Corporation
  • 11.4.5. Thermo Fisher Scientific, Inc.

12. Company Profiles

• 12.1. Abbott Laboratories
• 12.2. F. Hoffmann-La Roche Ltd
• 12.3. Siemens Healthineers AG
• 12.4. Danaher Corporation
• 12.5. Thermo Fisher Scientific Inc.
• 12.6. Becton, Dickinson and Company (BD)
• 12.7. bioMerieux S.A.
• 12.8. QuidelOrtho Corporation
• 12.9. EKF Diagnostics Holdings plc
• 12.10. Sekisui Diagnostics, LLC.
• 12.11. Trinity Biotech plc
• 12.12. Chembio Diagnostics, Inc.
• 12.13. Werfen
• 12.14. Nova Biomedical

13. Appendix

• 13.1. Available Customization
• 13.2. Related Reports